SAN CARLOS, Calif.--(BUSINESS WIRE)--Feb. 9, 2006--NeurogesX, Inc., a privately held specialty pharmaceutical company, today announced that a webcast presentation of positive Phase 3 trial results in painful HIV-associated sensory neuropathy (HIV-AN) is available on the company’s Web site at www.neurogesx.com. David Simpson, M.D., Professor of Neurology at Mount Sinai School of Medicine in New York and lead academic investigator in the NeurogesX trial, presented the results of the study at the 13th Annual Conference on Retroviruses and Opportunistic Infections (CROI). Dr. Simpson’s discussion was based on an abstract titled, “Controlled Study of High-Concentration Capsaicin Patch for Painful HIV-Associated Distal Sensory Polyneuropathy.”
